Iofetamine Hydrochloride I 123

CHEMBL1200360 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
335.6 g/mol
LogP
—
Phase
4

A radioactive brain imaging agent labeled with iodine-123, used in SPECT scanning to evaluate cerebral blood flow in conditions such as dementia and stroke. It crosses the blood–brain barrier and distributes in proportion to regional brain perfusion.

Masse moléculaire

335,6400 g/mol

TPSA

12,00 Ų

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)NC(C)Cc1ccc([123I])cc1.Cl

InChI

InChI=1S/C12H18IN.ClH/c1-9(2)14-10(3)8-11-4-6-12(13)7-5-11;/h4-7,9-10,14H,8H2,1-3H3;1H/i13-4;

Molecular Formula

C12H19ClIN

HBD / HBA

2 / 1

Liaisons Rotatives

4

Atomes Lourds

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A radioactive brain imaging agent labeled with iodine-123, used in SPECT scanning to evaluate cerebral blood flow in conditions such as dementia and stroke. It crosses the blood–brain barrier and distributes in proportion to regional brain perfusion.

Yes, Iofetamine Hydrochloride I 123 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200360. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 443997. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.